World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
33772
World Ranking
11671
National Ranking
5982

Overview

Bonnie S. Glisson is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a significant emphasis on Oncology, Surgery, Epidemiology, Pulmonary and Respiratory Medicine, and Otorhinolaryngology.

The scientist's work covers several main topics, including:

  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Head and Neck Cancer Studies
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Treatments and Mutations
  • Ear and Head Tumors
  • Salivary Gland Tumors Diagnosis and Treatment

Bonnie S. Glisson has published articles in multiple frequent academic venues such as:

  • Clinical Cancer Research
  • Cancer
  • Journal of Clinical Oncology
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Recent notable papers by this scientist include:

  • Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, 2021, Cancer Cell
  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer, 2020, Nature Cancer
  • Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer, 2021, Journal for ImmunoTherapy of Cancer
  • Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC, 2020, Journal of Thoracic Oncology

Their frequent co-authors include Renata Ferrarotto, John V. Heymach, Lauren A. Byers, J. Jack Lee, and Carl M. Gay.

Best Publications

  • Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

    Arlene A. Forastiere;Helmuth Goepfert;Moshe Maor;Thomas F. Pajak

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer

    Arlene A. Forastiere;Qiang Zhang;Randal S Weber;Moshe H. Maor

  • Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225

    Nancy Lee;Jonathan Harris;Adam S Garden;William Straube

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

    Triparna Sen;B. Leticia Rodriguez;Limo Chen;Carminia Della Corte

  • Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer

    Stephen G. Swisher;Jack A. Roth;John Nemunaitis;David D. Lawrence

  • Role of Topoisomerase II in Mediating Epipodophyllotoxin-induced DNA Cleavage

    Warren Ross;Tom Rowe;Bonnie Glisson;Jack Yalowich

  • Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

    C. Allison Stewart;Elizabeth M. Park;Lixia Diao

  • Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.

    Randal S. Weber;Brian A. Berkey;Arlene Forastiere;Jay Cooper

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

    Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  • Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

    Lauren Averett Byers;Jing Wang;Monique B. Nilsson;Junya Fujimoto

  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

    Charles M Rudin;M Catherine Pietanza;Todd M Bauer;Neal Ready

  • Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

    Erminia Massarelli;William William;Faye Johnson;Merrill Kies

  • Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer

    J. Nemunaitis;S.G. Swisher;T. Timmons;D. Connors

  • Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck Cancer

    Dong M. Shin;Nicholas J. Donato;Roman Perez-Soler;Hyung Ju C. Shin

  • Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial

    Nancy Y. Lee;Qiang Zhang;David G. Pfister;John Kim

  • Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

    F V Fossella;J S Lee;D M Shin;M Calayag

  • Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid Tumors

    Katherine M.W. Pisters;Robert A. Newman;Brenda Coldman;Dong M. Shin

  • Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

    Stephen G Swisher;Jack A Roth;Ritsuko Komaki;Jian Gu

  • Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

    F V Fossella;J S Lee;W K Murphy;S M Lippman

Frequent Co-Authors

John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Merrill S. Kies
Merrill S. Kies The University of Texas MD Anderson Cancer Center
Waun Ki Hong
Waun Ki Hong The University of Texas MD Anderson Cancer Center
Adam S. Garden
Adam S. Garden The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center
Dong M. Shin
Dong M. Shin Emory University
Scott M. Lippman
Scott M. Lippman University of California, San Diego
Fadlo R. Khuri
Fadlo R. Khuri American University of Beirut
Adel K. El-Naggar
Adel K. El-Naggar The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending traditional, on-campus programs. Many students opt for flexible online degrees that prepare them for rewarding roles in healthcare. For those interested in advanced practice, there are most affordable online nurse practitioner programs that offer both quality and value.

Nursing professionals can also advance their education by pursuing the cheapest online msn programs, designed to be financially accessible while providing robust training. Those already working as registered nurses can further their credentials and boost their career options with the cheapest rn to bsn online options.

For nurses interested in research, teaching, or leadership, doctoral programs can open new doors. Consider online phd nursing programs that combine flexibility and affordability. With these online pathways, healthcare professionals can advance their education and career while balancing work and personal commitments.

Best Scientists Citing Bonnie S. Glisson

Trending Scientists